José Antonio Lorente Garin
José Antonio Lorente Garin
HEAD OF SERVICE
Urologíaen/specialities/urologia
See more specialists on
Barcelonabarcelona
en/medical-staff/urologist
Dr. José Antonio Lorente Garin is a distinguished urologist and holds a Doctorate in Medicine and Surgery from the Universidad Autónoma de Barcelona , where he earned his degree in 1998. He currently serves as Head of Department at Hospital Quirónsalud Barcelona , further solidifying his reputation in the field of urology . Among his scientific contributions, the publication "FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study," published in the Journal of Urology in 2017, stands out. His work was recognized with the "Reviewer of the Month" award from Archivos Españoles de Urología in 2015. Furthermore, Dr. Lorente is a member of the Endourological Society (ES), reflecting his commitment to the scientific community and his continuous pursuit of excellence in his field.
Key information
- Recognition as Best Reviewer of the Month2015
- Latest Publication:Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels
- Belongs to:Endourological Society (ES)
Professional Details
Hospital Quirónsalud Barcelona
HEAD OF SERVICE
January 2023
Parc de Salut Hospital del Mar
Coordinator
January 2009
Universidad Autónoma de Barcelona
Associate Professor
January 1999
Hospital de Barcelona
Specialist doctor
January 1998
Hospital Vall DHebron Barcelona
Specialist doctor
January 1997
Hospital Vall DHebron Barcelona
Resident Physician
January 1992
Study
Bachelor of Medicine and Surgery
Universidad de Navarra
1990
Doctorate
Universidad Autónoma de Barcelona
1998
Specialized Healthcare Training
Urology Specialist
Another qualification
Diploma in Biostatistics in Health Sciences
Another qualification
Master's Degree in Clinical Management
Another qualification
Fellow of European Board of Urology
Another qualification
Diploma in Design and Statistics in Health Sciences
Associate Professor of Urology
Universidad Internacional de Cataluña
January 2015
Urology
Universidad Autónoma de Barcelona
January 1999
Associate Professor of Urology
Universidad Autónoma de Barcelona
January 1999
Differential molecular mechanisms of indolent and aggressive prostate cancer: identification of prognostic markers and therapeutic targets. Role of tumor stem cells
ISCIII
2010
Application of discrete event simulation to evaluate the benefit and budgetary impact of population-based cancer screening programs
ISCIII
2008
Integration of DNA, RNA and protein markers in a tool for the prognosis and diagnosis of human disease
EUROPEAN COMMISSION
2007
Study of the differences in gene expression between clinically significant prostate cancer and the latent and incidental variants
ISCIII
2007
Study of the molecular differences between latent, incidental, ‘insignificant’ and clinically significant prostate cancer
AECC Catalonia
2006
Randomized, double-blind, parallel-group trial comparing Casodex 150 mg (once daily) with placebo in non-metastatic PC
Zeneca
Efficacy and safety of Dutasteride vs placebo to reduce the risk of biopsy-detected prostate cancer
GlaxoSmithKline
Immunohistochemical study using tissue microarray (TMA) of the molecular expression pattern in prostate cancer
FIU
Study of bone turnover markers in patients with prostate, kidney and bladder cancer with bone metastases
Novartis
AGS-003-007
Argos Therapeutics, Inc.
European Multicenter Protocol to Assess Tumor Heterogenicity with a cell-cycle Progression Assay in Prostate Cancer Stage T1-3, N0, M0
Myriad Genetics GmbH
Pivotal Phase III trial to evaluate the efficacy and safety of a dispersible Vardenafil tablet versus placebo in the treatment of erectile dysfunction
Bayer
Integrated Spanish Bladder Cancer Study
EU 7th Framework Programme, MICINN
Phase III, randomized, double-blind trial to evaluate the efficacy and safety of ZD4054 10 mg daily in non-metastatic castration-resistant PC
Zeneca
Efficacy and safety of Dutasteride vs placebo… (Extended Phase III study)
GlaxoSmithKline
Phase III, double-blind, randomized, placebo-controlled clinical trial to evaluate the usefulness of extracorporeal shock wave therapy in patients with CPSD
Hospital Quironsalud Barcelona
International epidemiological study on the microbiology of uncomplicated UTIs
Zambon
Prospective observational post-authorization study to evaluate the prevalence of metabolic syndrome in prostate cancer patients before and after 12 months of treatment with LHRH analogues
IPSEN
Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients
Novartis
A 2-year, double-blind, placebo-controlled, multicenter, randomized study of alfuzosin 10 mg/day in men at increased risk of LUTS and BPH progression
Sanofi-Aventis
Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels
Journal Article
Advances in Kidney Transplantation. Surgical Options in Standard and Complex Kidney Transplantation
Book chapter
Prostate Cancer in Medical Oncology
Book chapter
PROSTATE CANCER. MULTIDISCIPLINARY APPROACH. RRP, perineal and laparoscopic PR
Book chapter
DIAGNOSIS AND TREATMENT OF INFECTIONS IN PRIMARY CARE. L. Drobnic – ‘Fournier’s Gangrene’
Book chapter
LABORATORY DIAGNOSIS OF PROSTATE CANCER: PROSTATE MARKERS
Book chapter
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study
Journal Article
Consensus Guide for the management of CPRC in Catalonia
Book chapter
ONCOLOGY MANUALS. PROSTATE CANCER
Book chapter
PROSTATE TUMOR MARKERS
Book chapter
Metabolic Syndrome and its Components in Prostate Cancer Patients under Androgen Deprivation Therapy
Journal Article
OUR EXPERIENCE WITH TRIGONOPREVIC PROSTATOTOMY (TCP): WHEN IT IS INDICATED AND ITS EFFICACY
Book chapter
PSA AND FREE PSA: AN UPDATED VIEW OF THE LABORATORY DIAGNOSIS OF PROSTATE CANCER
Book chapter
Quality of life in patients with non-muscle-invasive bladder cancer: One-year results of a multicentre prospective cohort study
Journal Article
TREATISE ON UROLOGICAL ONCOLOGY. Surgical treatment of bladder carcinoma
Book chapter
TREATISE ON UROLOGY. SYMPTOMATIC URINARY TRACT INFECTIONS
Book chapter
MEDICAL TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Book chapter
Endourological Society (ES)
Asociación Americana de Urología (AUA)
Asociación Europea de Urología (EAU)
Asociación Ibero-Americana de Neuro-Urología y Uro-Ginecología (SINUG)
Asociación Española de Urología (AEU)
Societat Catalana d’Urologia (SCU)
European Robotic Urological Society (ERUS)
Reial Academia de Ciències Mèdiques de Catalunya i Balears
Recognition as Best Reviewer of the Month
Archivos Españoles de Urología
PROMICA Research Grant
Astellas
Assistance for training in urological laparoscopy
Asociación Española de Urología
Research aid
Fundación para la Investigación en Urología
Extraordinary Doctoral Award
Universidad Autónoma de Barcelona
1st National Prize for Best Poster
Asociación Española de Urología
Extraordinary award for best communication at the LX National Congress
Asociación Española de Urología
First Prize of the Residents' Session
Associació Catalana d’Urologia
Research grant (internal funding)
Hospital Universitari Vall d’Hebron
English
C
Catalan
C
Castilian
C
Make an appointment with this professional
Vídeos de
Consulta el contenido multimedia de este profesional.
Hospitals
Book an appointment now at one of our hospitals.
Hospital Quirónsalud Barcelona
Plaza Alfonso Comín, 5
08023 Barcelona
Articles on
Browse the latest articles on Tu canal de salud.
¿No tienes seguro de salud?
Con nuestros Planes de Salud Quirónsalud Connect tendrás un médico de medicina general todos los días las 24 horas. Y además gestor personal y medición facial de constantes vitales.